S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
NASDAQ:KZIA

Kazia Therapeutics - KZIA Stock Forecast, Price & News

$1.00
-0.01 (-0.99%)
(As of 01/27/2023 08:55 PM ET)
Add
Compare
Today's Range
$0.97
▼
$1.04
50-Day Range
$0.50
▼
$1.05
52-Week Range
$0.50
▼
$8.61
Volume
32,100 shs
Average Volume
104,019 shs
Market Capitalization
$13.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Kazia Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.25mentions of Kazia Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.05) to ($1.01) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.87 out of 5 stars

Medical Sector

1045th out of 1,049 stocks

Pharmaceutical Preparations Industry

510th out of 514 stocks

See Top Rated MarketRank™ Stocks Here

KZIA stock logo

About Kazia Therapeutics (NASDAQ:KZIA) Stock

Kazia Therapeutics Ltd. is a clinical stage oncology company It engages in the pharmaceutical research and development business. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Receive KZIA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KZIA Stock News Headlines

January 25, 2023 | finance.yahoo.com
Trade Alert: Stephen Abolakian At Kazia Therapeutics Limited (ASX:KZA), Has Just Spent AU$1m Buying 54% More Shares
January 24, 2023 | americanbankingnews.com
Kazia Therapeutics Limited (NASDAQ:KZIA) Sees Large Decline in Short Interest
January 30, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
January 18, 2023 | finance.yahoo.com
Kazia Therapeutics CEO talks $4.5 million capital raise
January 16, 2023 | msn.com
Kazia raises A$4.5M to progress R&D programs
January 16, 2023 | finance.yahoo.com
KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS
December 20, 2022 | proactiveinvestors.com.au
Kazia Therapeutics exploring use of lead asset in other cancers: Edison Investment Research
December 19, 2022 | finance.yahoo.com
Kazia Therapeutics (KZIA): Collaboration May Expand Utility to Combo Therapies
January 30, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
December 15, 2022 | finance.yahoo.com
KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING
December 12, 2022 | finance.yahoo.com
KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
December 7, 2022 | proactiveinvestors.com
Kazia Therapeutics’ upcoming top-line data for EVT801 expected to be a share price catalyst: Edison Investment Research
December 5, 2022 | proactiveinvestors.com.au
Kazia Therapeutics talks positive pre-clinical data for EVT801
November 9, 2022 | finance.yahoo.com
KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING
November 2, 2022 | seekingalpha.com
Kazia Therapeutics provides cash outlook
November 2, 2022 | finance.yahoo.com
Kazia Therapeutics (KZIA): Q123 Cash Flows in Line with Our Estimates
October 27, 2022 | benzinga.com
Thinking about buying stock in UserTesting, Kazia Therapeutics, Shopify, Ford Motor, or View?
October 27, 2022 | seekingalpha.com
Kazia jumps 31% on pre-clinical data for skin cancer therapy
October 27, 2022 | finance.yahoo.com
KAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA
October 27, 2022 | finance.yahoo.com
Kazia Therapeutics Reveals Paxalisib Preclinical Data In Melanoma Animal Models
October 20, 2022 | uk.investing.com
Kazia Therapeutics Ltd (KZA)
October 6, 2022 | finance.yahoo.com
PNOC CLINICAL STUDY OF KAZIA'S PAXALISIB IN CHILDHOOD BRAIN CANCER EXPANDS INTERNATIONALLY
October 5, 2022 | proactiveinvestors.com.au
Kazia Therapeutics takes Phase 2 study of paxalisib international; opens two sites in Australia
September 27, 2022 | reuters.com
Kazia Therapeutics Ltd
September 26, 2022 | finance.yahoo.com
Novogen Limited (KZIA) Could Find Support Soon, Here's Why You Should Buy the Stock Now
September 9, 2022 | finance.yahoo.com
KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT 24th ANNUAL GLOBAL INVESTMENT CONFERENCE
September 8, 2022 | finance.yahoo.com
KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMO
See More Headlines
Receive KZIA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KZIA Company Calendar

Today
1/30/2023
Fiscal Year End
6/30/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KZIA
CUSIP
N/A
CIK
1075880
Web
www.kaziatherapeutics.com
Phone
(129) 472-4101
Fax
61-2-9476-0388
Employees
2,021
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.62
Quick Ratio
1.62

Sales & Book Value

Annual Sales
$11.35 million
Price / Sales
1.22
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.97 per share
Price / Book
1.03

Miscellaneous

Outstanding Shares
13,880,000
Free Float
13,737,000
Market Cap
$13.88 million
Optionable
Not Optionable
Beta
2.11

Key Executives

  • James Stuart Garner
    Chief Executive Officer, MD & Executive Director
  • Karen R. Krumeich
    Chief Financial Officer
  • John E. Friend
    Chief Medical Officer
  • Catherine Hill
    Secretary

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions













KZIA Stock - Frequently Asked Questions

Should I buy or sell Kazia Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kazia Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" KZIA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KZIA, but not buy additional shares or sell existing shares.
View KZIA analyst ratings or view top-rated stocks.

How have KZIA shares performed in 2023?

Kazia Therapeutics' stock was trading at $0.6149 at the beginning of the year. Since then, KZIA stock has increased by 62.6% and is now trading at $1.00.
View the best growth stocks for 2023 here.

Are investors shorting Kazia Therapeutics?

Kazia Therapeutics saw a increase in short interest in January. As of January 15th, there was short interest totaling 247,100 shares, an increase of 64.2% from the December 31st total of 150,500 shares. Based on an average daily volume of 350,200 shares, the days-to-cover ratio is currently 0.7 days.
View Kazia Therapeutics' Short Interest.

What other stocks do shareholders of Kazia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kazia Therapeutics investors own include Fulcrum Therapeutics (FULC), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Idera Pharmaceuticals (IDRA), MEI Pharma (MEIP), Pfizer (PFE), Translate Bio (TBIO), VYNE Therapeutics (VYNE) and Allena Pharmaceuticals (ALNA).

What is Kazia Therapeutics' stock symbol?

Kazia Therapeutics trades on the NASDAQ under the ticker symbol "KZIA."

How do I buy shares of Kazia Therapeutics?

Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kazia Therapeutics' stock price today?

One share of KZIA stock can currently be purchased for approximately $1.00.

How much money does Kazia Therapeutics make?

Kazia Therapeutics (NASDAQ:KZIA) has a market capitalization of $13.88 million and generates $11.35 million in revenue each year.

How many employees does Kazia Therapeutics have?

The company employs 2,021 workers across the globe.

How can I contact Kazia Therapeutics?

Kazia Therapeutics' mailing address is Three International Towers Level 24 300 Barangaroo Avenue, Sydney C3, 2000. The official website for the company is www.kaziatherapeutics.com. The company can be reached via phone at (129) 472-4101, via email at investment.consultant@novogen.com, or via fax at 61-2-9476-0388.

This page (NASDAQ:KZIA) was last updated on 1/30/2023 by MarketBeat.com Staff